Lexicon Pharma (LXRX) Tops Q2 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- Wall St futures rise as AI stocks catch their breath; midterms in focus
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops more than 4% on talks aimed at ending US-Iran war
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
Tweet
Share
E-mailGet Alerts LXRX Hot Sheet
Price: $1.42 --0%
EPS Growth %: -50.0%
Financial Fact:
Subscription and license fees: 31K
Today's EPS Names:
LTBR, AES, SYRS, More
EPS Growth %: -50.0%
Financial Fact:
Subscription and license fees: 31K
Today's EPS Names:
LTBR, AES, SYRS, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q2 EPS of ($0.27), $0.05 better than the analyst estimate of ($0.32). Revenue for the quarter came in at $376 million versus the consensus estimate of $360 thousand.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Public Service Enterprise (PEG) Misses Q3 EPS by 4c ; Offers Guidance
- Lumentum Holdings (LITE) Tops Q1 EPS by 36c ; Offers Guidance
- Tempus AI, Inc (TEM) Tops Q3 EPS by 6c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
